Health breakthroughs and money matters, in plain words

Home » UK Trial to Test CY-101 in Rare Cancer Patients Through 2032

UK Phase 2 Trial Opens to Test CY-101 in Rare Adrenal Cancer

By

–

UK Trial to Test CY-101 in Rare Cancer Patients Through 2032

Cancer Research UK has opened a Phase 2 trial of CY-101 for people with advanced adrenocortical carcinoma, a rare and aggressive cancer. The study, called CLARITY, is for patients whose disease has spread despite conventional treatment.

Six UK sites are open: Manchester, Leeds, Liverpool, and in London, Guy’s Hospital, the Royal Marsden and Imperial College. The team wants to recruit 41 patients, and more sites across Europe are planned. Because the trial is randomised, participants will go into one of two arms, each testing a different dose of the drug.

What CY-101 does

CY-101, also known as getacatetide, is a peptide immunotherapy from the biotech company Cytovation. It is injected into the tumor. The aim is to turn immune-resistant “cold” tumors, a group that includes adrenocortical carcinoma, into immune-active “hot” ones. It does that by stimulating immune activity inside the tumor while blocking the Wnt/β-catenin signalling pathway, a key driver of resistance to immunotherapy in cancers like this one.

Cancer Research UK, Cytovation and the Norwegian Cancer Society are collaborating on the drug’s clinical development.

What the partners said

Dr Lars Erwig, director of the Centre for Drug Development at Cancer Research UK, said “People living with ACC deserve better treatment options” and that the charity was pleased the study had reached this milestone.

Cytovation chief executive Dr Lars Prestegarden pointed to earlier work. Activity seen in patients with the disease in the company’s Phase 1 CICILIA trial gave “strong reason to advance into a dedicated Phase 2 study,” he said, adding that treatment options for these patients “remain very limited.”

The inclusion and exclusion criteria are extensive and listed on the Cancer Research UK website. Patients who are interested should talk to their specialist. The patient group AMEND says it will follow the trial and update the adrenocortical carcinoma community on its progress.

Sources

Get breaking stories first on our Telegram channel.

More stories by

Most read

Health & Medicine

Personal Finance

Cancer News

Health News